This HDAC isotype selectivity may be related to the drugs' activity against the gynecologic cancer cell lines as HDAC 1/2/3 have been implicated in ovarian tumor malignancy and growth [56], while HDAC2 is overexpressed in cervical cancer carcinogenesis [57]. The gene discussed is HDAC2; the disease is cervical carcinoma.